Abstract:Spinal muscular atrophy (SMA) is a severe autosomal recessive motor neuron disease caused by the loss of SMN1, which encodes a protein essential for motor neuron survival. SMA patients have one or more copies of an alternate SMN gene, SMN2, which is nearly identical to SMN1. SMN2 differs at a single nucleotide from SMN1 which results in the skipping of exon 7 in the mRNA and produces an unstable protein (SMNΔ7). Therapeutic approaches that have been undertaken include (1) replacement of SMN1 by gene delivery mediated by adeno-associated virus serotype 9 (AAV9) (Zolgensma), (2) correction of the aberrant SMN2 splicing using an antisense oligonucleotide (ASO) or small molecule (nusinersin, risdiplam), and (3) increased expression of SMN2 mediated by histone deacetylase (HDAC) inhibitors. Two of these three approaches have given rise to successful treatments for SMA, but they are very expensive, and their long-term safety is not well known. In addition, the ability of ASOs and viral vectors to reach their targets in the CNS with peripheral administration is limited. Small molecules may cross the brain-blood barrier when orally delivered and can be discontinued if needed to mitigate adverse effects. This Editorial highlights this study by Pagliarni et al. in which they used combined treatment of cell models of SMA with an ASO and an orally delivered HDAC inhibitor (panobinostat) to overcome the limitations of a single-therapeutic approach. Panobinostat enhanced the expression of SMN2, increasing the amount of SMN2 mRNA available for splicing correction mediated by the ASO. In addition, panobinostat increased exon 7 retention in the SMN2 mRNA. This combinatorial treatment might allow lower or less frequent ASO doses, reducing the need for repeated intrathecal administration. The combined effects of panobinostat and nusinersen can now be tested in SMA animal models to determine whether this approach will be translatable to patients.

Base editing-mediated splicing correction therapy for spinal muscular atrophy

Base editing rescue of spinal muscular atrophy in cells and in mice

Disruption of splicing-regulatory elements using CRISPR/Cas9 to rescue spinal muscular atrophy in human iPSCs and mice

Base editing as a genetic treatment for spinal muscular atrophy

Optimization of base editors for the functional correction of SMN2 as a treatment for spinal muscular atrophy

Single-Swap Editing for the Correction of Common Duchenne Muscular Dystrophy Mutations

Correction of RNA Splicing with Antisense Oligonucleotides as a Therapeutic Strategy for a Neurodegenerative Disease

Correction of a Splicing Defect in a Mouse Model of Congenital Muscular Dystrophy Type 1A Using a Homology-Directed-repair-independent Mechanism.

Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing

Improvement of TaC9‐ABE mediated correction of human SMN2 gene

Correction of human non-sense mutation via adenine base editing for Duchenne muscular dystrophy treatment in mouse

Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing

Targeted-Deletion of a Tiny Sequence via Prime Editing to Restore SMN Expression

Efficient correction of Duchenne muscular dystrophy mutations by SpCas9 and dual gRNAs

Correction of Diverse Muscular Dystrophy Mutations in Human Engineered Heart Muscle by Single-Site Genome Editing

Combinatorial treatment for spinal muscular atrophy: An Editorial for 'Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells' on page 264

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy

Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model

Discovery and Optimization of Small Molecule Splicing Modifiers of Survival Motor Neuron 2 as a Treatment for Spinal Muscular Atrophy

Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing

Mini-dCas13X–mediated RNA editing restores dystrophin expression in a humanized mouse model of Duchenne muscular dystrophy